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Editorial on the Research Topic
The Development of New Classes of Hypoxia Mimetic Agents for Clinical Use
Hypoxia-inducible factors (HIFs) are evolutionarily conserved transcription factors that regulate
the bulk of hypoxic transcriptional responses in most mammalian cells. Transcriptionally active
HIF levels rise at sub-physiological concentrations of oxygen inducing upregulation of a range of
genes with activities ranging from cell protection to apoptosis according to the specific context and
cell type. In humans, there are three knownHIF isoforms; HIF-1 (first described in 1992) (Semenza
andWang, 1992) with a dominant role in the response to acute hypoxia, HIF-2 driving the response
to chronic hypoxia, and HIF-3, a negative regulator of hypoxia-inducible gene expression (Graham
and Presnell, 2017). Prolyl hydroxylase domain enzymes (PHDs), first described in 2001, provided
the mechanism for HIF regulation via hydroxylation (Bruick, 2001). The PHDs themselves are
2-oxoglutarate (2OG) and non-heme-Fe(II)-dependent dioxygenase family members, all requiring
Fe2+, 2OG, O2, and ascorbate for catalytic activity. Following on from their discovery three PHD
isoforms (PHD1-3) have now been identified in mammalian tissue. PHD2, in particular, due to its
slow reaction with oxygen, was identified as the key human oxygen sensor (Berra et al., 2003).
The direct connection between hydroxylase-dependent catalysis and physiological responses to
hypoxia identify modulation of HIF hydroxylase activity as a potential therapeutic for use in a range
of disease states including anemia, ischaemic diseases, and cancer. The term “hypoxia mimetic
agent” is now widely used to indicate biological or chemical molecules which are used to activate
the HIF pathway. Chemicals with a similar structure to 2OG, a tricarboxylic acid cycle (TCA)
intermediate and a substrate of hydroxylase, compete with 2OG for binding sites at HIF prolyl
hydroxylases and asparaginyl hydroxylase, factor inhibiting HIF (FIH), inhibit their activities, and
stabilize HIF.
At current standing we are aware of four HIF hydroxylase inhibitors in clinical use or trial for
anemia treatment in patients with chronic kidney disease (CKD). Small molecule HIF hydroxylase
inhibitors have a number of advantages over other drugs such as low price, good compliance, and
few allergic reactions. The pleiotropic and contrasting nature of the hypoxic response, driven by
the large number of components involved, and the abundance of human 2OG oxygenases, ∼60,
create an importance around the development of highly potent and selective PHD inhibitors for
clinical use (Yeh et al., 2017). This special issue is focused on the current development of hypoxia
mimetic agents for clinical uses. We have covered a wide range of topics to highlight state of the
art, limitations, and promises in the field, of interest to a broad community of researchers engaged
in drug discovery.
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In this special issue, Davis et al. have reviewed the application
of PHD inhibitors for the treatment of ischaemic stroke.
Neuroprotection via HIF-1α stabilization for ischaemic stroke is
still a controversial topic; HIF downstream genes mediate both
adaptive and pathological processes in stroke. Table 2, Davis et al.,
provides a valuable summary of studies with PHD inhibitors
in preclinical stroke studies drawing the conclusion that the
beneficial effects of HIF inhibition overweigh the side effects of
the chemicals. The neuroprotection conferred by these agents
unsurprisingly but importantly depends on the cell type and
magnitude of ischaemic injury where some harmful effects of HIF
activation can be eliminated by choosing the optimal window for
PHD inhibitor administration.
Chen et al. emphasize that HIF PHD inhibition is not
the same as HIF activation. Although HIF-α is the best
studied substrate of PHD, the PHD has a number of
other substrates (Chen et al., 2012). The inhibition of HIF
hydroxylase not only exerts pleiotropic neuroprotective effects
as a consequence of HIF induction, but also has anti-oxidant
and anti-inflammatory effects. HIF has dual roles in reactive
oxygen species (ROS) formation: reduction by suppression of
mitochondrial TCA, or increase via NADPH oxidase, a HIF
pathway target gene. Nevertheless, HIF PHD inhibition reduced
ROS formation during ischemia/reperfusion. Developing further
understanding of the HIF pathway and its relation with ROS
may facilitate the advancement of pharmacological therapies for
ischaemic stroke.
Wu et al. systemically review the role of hypoxia, HIF
and PHD inhibitors in neural stem cell (NSC) proliferation
and differentiation. The main NSC niches are located in
the hippocampus and the subventricular zone at 1–5%
O2. Mild hypoxia (2.5–5% O2) is the optimal condition
for the proliferation of NSCs in comparison with 1 or
21% O2. Hypoxia promotes the proliferation of NSCs via
a number of signaling pathways, such as the WNT/β-
catenin, MEK/ERK and the PI3K/AKT signaling pathways.
Hypoxia preconditioning increases NSC proliferation
via the HIF-1α/AKT pathway. Additionally, WNT/β-
catenin signaling is implicated in the effects of HIF-1α
on NSC proliferation. Lastly, the authors described how
the employment of hypoxia mimetic agents to provide
HIF-1α stabilization might facilitate the expansion of
NSCs in vitro. Novel compounds (e.g., FG4497) can induce
neurogenesis without causing toxicity. Thus, the development
of new specific and effective PHD inhibitors could offer
a valid tool for the application of NSC transplantation in
neurodegenerative disease.
Finally, Al Tameemi et al. review the effects of hypoxia
on cancer cell metabolism. Hypoxia induces a number of protein
changes in tumor cells which may initiate cell cycle arrest,
differentiation, necrosis, and apoptosis, as well as stimulate tumor
growth, invasion, and metastasis by facilitating acclimatization
and survival. Under atmospheric oxygen conditions (21% O2),
in vitro stem cells lose their stemness characteristics. In vivo
normal adult stem cells are maintained in hypoxic conditions,
typically defined as 1% oxygen. The stimulation of cancer cell
stemness by HIFs is well-documented, with studies revealing
HIF-1α and HIF-2α to be central to cancer stem cells stemness.
The stemnesss stimulation is influencedmore by HIF-2α (e.g., via
Notch, Oct4, Sox2) than by HIF-1α (e.g., via glycolysis pathway).
Furthermore, HIF-1α demonstrates tumor promoting capability.
It is proposed that activating HIF-1α initiates autophagy and
aerobic glycolysis; this provides cells surrounding the cancer cells
with energy necessary to promote their growth. Glycolysis in
tumors could be driven by HIF-1α stabilization, independently
of the hypoxic environment. Additionally, HIF-1α enables cells
to regulate to the reduced intracellular pH that occurs as a
consequence of increased anaerobic glycolysis and the resulting
lactic acid production.
In conclusion, the present issue has brought together, within a
single place, some of the latest and most critical developments
in current and emerging hypoxia mimetic agents. Roxadustat
(FG4592) is currently licensed for treatment of CKD in China
while other HIF PHD inhibitors are in phase II and III
clinical trials. The HIF pathway modulates the expression of
hundreds of human genes and for this reason more specific
and potent small molecules to inhibit PHD are needed for the
treatment of a wider range of diseases. Currently, no single drug
specifically inhibits PHD isoforms and FIH, but some do provide
differential inhibition. Agents stabilizing HIF via FIH inhibition
warrant further exploration.
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